Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Amgen, Inc. : Outgoing Amgen CEO May Receive $49 Million After Retirement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2012 | 10:52pm CET
   By Peter Loftus 
   Of  
 

The outgoing leader of biotechnology company Amgen Inc. (AMGN) could receive payments and deferred compensation totaling more than $49 million after he retires.

Kevin Sharer, 64, plans to step down as chief executive in May and as chairman at the end of 2012, after more than a decade at the helm of the Thousand Oaks, Calif., company. President and Chief Operating Officer Robert Bradway, 49, will succeed Sharer as CEO.

Sharer isn't the only retiring drug company CEO to be poised for hefty post-retirement payments. Johnson & Johnson (JNJ) disclosed earlier this month that the estimated value of William Weldon's pension and deferred compensation was more than $143 million. Weldon is stepping down as CEO in April but will remain chairman for an undisclosed period.

In a proxy statement filed with the Securities and Exchange Commission this week, Amgen provided details about payments and deferred compensation that Sharer could receive after retirement. The figures are estimated values as of Dec. 31, 2011, and the actual values could change by the time he retires.

One category of post-retirement payments had an estimated current value of $26.9 million as of Dec. 31. These include: $6.6 million in accelerated unvested stock options; $7.8 million in accelerated unvested restricted stock units; and $12.6 million for the value of performance units for the years 2010 to 2013.

Restricted stock units are convertible into Amgen shares upon vesting, while performance units are rights to receive shares based on pre-established performance goals achieved over a period typically lasting three years.

Some of these amounts were calculated using the closing price of Amgen shares on Dec. 31, of $64.21. The stock ended Friday's trading up 4 cents at $66.66.

In addition, Sharer will be able to collect deferred compensation that had an aggregate balance of $22.5 million as of Dec. 31. This includes contributions to his retirement plan and portions of compensation from previous years that Sharer was permitted to defer.

Amgen spokeswoman Christine Regan noted that the $22.5 million balance included money Sharer had previously earned, as well as contributions from a company retirement program that is available to all regular U.S. Amgen employees.

Sharer won't be paid severance upon retirement, Regan said. Sharer will continue to collect his salary through the end of May and is entitled to a prorated portion of his 2012 bonus.

For 2011, Sharer's total compensation was valued at $18.9 million, down 11% from the $21.1 million value of his compensation for 2010 mainly because of a decline in the value of option awards.

Elements of Sharer's 2011 compensation included: $1.8 million in base salary, $9 million in stock awards, $2.4 million in option awards and $4.9 million in non-equity incentive plan compensation.

Amgen's incoming CEO Bradway received compensation valued at $7.1 million for 2011, down from $7.8 million for 2010.

This month, the compensation committee of Amgen's board approved a 36% increase in Bradway's base salary to $1.4 million in connection with his promotion to CEO.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
01/17 AMGEN : FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib..
01/17 AMGEN : Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Tr..
01/15 AMGEN : Astellas Pharma Inc - Repatha SC Injection 420 mg Auto Mini Doser Launch..
01/11 AMGEN : FDA Approves XGEVA® denosumab For The Prevention Of Skeletal-Related Eve..
01/11 AMGEN : "Drug Delivery Device with Live Button Or User Interface Field" in Paten..
01/11 AMGEN : Patent Application Titled "Feed Media" Published Online (USPTO 201703698..
01/11 AMGEN : Patent Issued for Refolding Proteins Using a Chemically Controlled Redox..
01/11 AMGEN : Research Conducted at Amgen Has Provided New Information about Antibodie..
01/11 AMGEN : New Biologics Findings from Amgen Described (Accelerating patient access..
01/11 AMGEN : European Medicines Agency Accepts Filing for EVENITY
More news
News from SeekingAlpha
01/17 FDA OKs inclusion of new OS data to label of Amgen's Kyprolis
01/16 It's Time For The Next Generation Dividend Growth Model Portfolio
01/16 A REAL DIVIDEND GROWTH MACHINE : 2017 Portfolio Review
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/16 Biotech Daily Digest For January 16th
Financials ($)
Sales 2017 22 893 M
EBIT 2017 11 763 M
Net income 2017 8 360 M
Finance 2017 6 868 M
Yield 2017 2,40%
P/E ratio 2017 16,90
P/E ratio 2018 16,64
EV / Sales 2017 5,66x
EV / Sales 2018 5,48x
Capitalization 136 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 192 $
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN6.69%134 685
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287